CN115884971B - 取代的哌啶化合物及其用途 - Google Patents

取代的哌啶化合物及其用途 Download PDF

Info

Publication number
CN115884971B
CN115884971B CN202180044081.3A CN202180044081A CN115884971B CN 115884971 B CN115884971 B CN 115884971B CN 202180044081 A CN202180044081 A CN 202180044081A CN 115884971 B CN115884971 B CN 115884971B
Authority
CN
China
Prior art keywords
azabicyclo
mmol
compound
added
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180044081.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN115884971A (zh
Inventor
吉田融
北阳一
小竹真
反町启一
大房俊行
元木贵史
浅羽太郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Priority to CN202411462171.6A priority Critical patent/CN119258067A/zh
Priority to CN202411459551.4A priority patent/CN119235864A/zh
Publication of CN115884971A publication Critical patent/CN115884971A/zh
Application granted granted Critical
Publication of CN115884971B publication Critical patent/CN115884971B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pain & Pain Management (AREA)
CN202180044081.3A 2020-07-17 2021-07-15 取代的哌啶化合物及其用途 Active CN115884971B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202411462171.6A CN119258067A (zh) 2020-07-17 2021-07-15 取代的哌啶化合物及其用途
CN202411459551.4A CN119235864A (zh) 2020-07-17 2021-07-15 取代的哌啶化合物及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-122864 2020-07-17
JP2020122864 2020-07-17
PCT/JP2021/026649 WO2022014680A1 (ja) 2020-07-17 2021-07-15 置換ピペリジン化合物及びその用途

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202411459551.4A Division CN119235864A (zh) 2020-07-17 2021-07-15 取代的哌啶化合物及其用途
CN202411462171.6A Division CN119258067A (zh) 2020-07-17 2021-07-15 取代的哌啶化合物及其用途

Publications (2)

Publication Number Publication Date
CN115884971A CN115884971A (zh) 2023-03-31
CN115884971B true CN115884971B (zh) 2024-11-05

Family

ID=79291962

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202180044081.3A Active CN115884971B (zh) 2020-07-17 2021-07-15 取代的哌啶化合物及其用途
CN202411459551.4A Pending CN119235864A (zh) 2020-07-17 2021-07-15 取代的哌啶化合物及其用途
CN202411462171.6A Pending CN119258067A (zh) 2020-07-17 2021-07-15 取代的哌啶化合物及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202411459551.4A Pending CN119235864A (zh) 2020-07-17 2021-07-15 取代的哌啶化合物及其用途
CN202411462171.6A Pending CN119258067A (zh) 2020-07-17 2021-07-15 取代的哌啶化合物及其用途

Country Status (19)

Country Link
US (1) US11479552B2 (enExample)
EP (1) EP4151277A4 (enExample)
JP (1) JP7190612B2 (enExample)
KR (1) KR20230040953A (enExample)
CN (3) CN115884971B (enExample)
AR (1) AR122973A1 (enExample)
AU (1) AU2021308053A1 (enExample)
BR (1) BR112022026161A2 (enExample)
CA (1) CA3187835A1 (enExample)
CL (1) CL2022003666A1 (enExample)
CO (1) CO2022018446A2 (enExample)
IL (1) IL299125B1 (enExample)
MX (1) MX2022016388A (enExample)
PE (1) PE20231103A1 (enExample)
PH (1) PH12022553488A1 (enExample)
TW (1) TWI888599B (enExample)
UA (1) UA129636C2 (enExample)
WO (1) WO2022014680A1 (enExample)
ZA (1) ZA202213562B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI4065585T1 (sl) 2019-11-25 2025-11-28 Alkermes, Inc. Substituirane makrociklične spojine ter z njimi povezani postopki zdravljenja
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US20250051322A1 (en) * 2022-01-14 2025-02-13 Eisai R&D Management Co., Ltd. Crystal of substituted piperidine compound, salts of substituted piperidine compound, and crystals thereof
JP7591592B2 (ja) * 2022-01-14 2024-11-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 置換ピペリジン化合物を含有する医薬
IL319940A (en) * 2022-10-07 2025-05-01 Kissei Pharmaceutical Cyclopentane compound
CN120129521A (zh) * 2022-10-31 2025-06-10 武田药品工业株式会社 食欲素2型受体激动剂的给药
JPWO2024128305A1 (enExample) 2022-12-16 2024-06-20
TW202502342A (zh) 2023-06-02 2025-01-16 日商武田藥品工業股份有限公司 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2025137359A1 (en) 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Assay methods to identify a disease
WO2025229493A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101035792A (zh) * 2004-10-20 2007-09-12 神经研究公司 新颖的二氮杂双环芳基衍生物和它们的医药用途
CN105209468A (zh) * 2013-03-13 2015-12-30 詹森药业有限公司 取代的7-氮杂二环化合物以及它们作为食欲素受体调节剂的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG34208A1 (en) 1995-03-01 1996-12-06 Guy Andrew Vaz Blast and fragment resistant polyurethane boot sole for safety footwear
WO1996034877A1 (en) 1995-05-05 1996-11-07 Human Genome Sciences, Inc. Human neuropeptide receptor
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US6159605A (en) 1997-02-18 2000-12-12 Dainichiseika Color & Chemicals Mfg. Co., Ltd. Ink-jet recording sheet
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
KR100327888B1 (ko) 1999-07-14 2002-03-09 정숭렬 도로포장 파손촉진 시험장치의 무선제어 시스템
US7547693B2 (en) * 2003-09-22 2009-06-16 Banyu Pharmaceutical Co. Ltd. Piperidine derivative
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101035792A (zh) * 2004-10-20 2007-09-12 神经研究公司 新颖的二氮杂双环芳基衍生物和它们的医药用途
CN105209468A (zh) * 2013-03-13 2015-12-30 詹森药业有限公司 取代的7-氮杂二环化合物以及它们作为食欲素受体调节剂的用途

Also Published As

Publication number Publication date
PE20231103A1 (es) 2023-07-19
US20220017517A1 (en) 2022-01-20
CA3187835A1 (en) 2022-01-20
MX2022016388A (es) 2023-01-30
JP7190612B2 (ja) 2022-12-15
JPWO2022014680A1 (enExample) 2022-01-20
CL2022003666A1 (es) 2023-05-26
AR122973A1 (es) 2022-10-19
CN119258067A (zh) 2025-01-07
UA129636C2 (uk) 2025-06-18
AU2021308053A1 (en) 2023-02-02
ZA202213562B (en) 2023-10-25
IL299125A (en) 2023-02-01
CN119235864A (zh) 2025-01-03
PH12022553488A1 (en) 2024-04-22
KR20230040953A (ko) 2023-03-23
TW202216705A (zh) 2022-05-01
CN115884971A (zh) 2023-03-31
WO2022014680A1 (ja) 2022-01-20
EP4151277A1 (en) 2023-03-22
CO2022018446A2 (es) 2023-03-07
EP4151277A4 (en) 2024-06-26
IL299125B1 (en) 2025-11-01
TWI888599B (zh) 2025-07-01
US11479552B2 (en) 2022-10-25
BR112022026161A2 (pt) 2023-01-31

Similar Documents

Publication Publication Date Title
CN115884971B (zh) 取代的哌啶化合物及其用途
CN110831945B (zh) 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
TWI378101B (en) Pyridine derivatives and their use in the treatment of psychotic disorders
TW201018663A (en) Fluorene compound and pharmaceutical use thereof
CN107257801A (zh) 选择性bace1抑制剂
KR101800140B1 (ko) 벤조티아졸론 화합물
TW202432509A (zh) 對於食慾素-2受體拮抗劑之製備有用之方法及化合物、以及雜質少之萊博雷生
EP4438602A1 (en) Crystal of substituted piperidine compound, salts of substituted piperidine compound, and crystals thereof
JP7591592B2 (ja) 置換ピペリジン化合物を含有する医薬
RU2840772C1 (ru) Замещенные пиперидиновые соединения и их применение
HK40083601A (en) Substituted piperidine compound and application thereof
TW202340145A (zh) 氘化有機化合物及其用途
TW202542144A (zh) 取代哌啶化合物及其用途
EA045865B1 (ru) Замещенные пиперидиновые соединения и их применение
HK40083601B (zh) 取代的哌啶化合物及其用途
WO2025146480A1 (en) 2-azabicyclo[2.1.1]hexane derivatives useful in the treatment of mitochondrial disorders
CA2882877A1 (en) Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
WO2023179758A1 (zh) 稠合三并环衍生物或其可药用盐的结晶
NZ621089B2 (en) Benzothiazolone compound
HK1242680A1 (en) Salts of benzothiazolone compound as beta-2-adrenoceptor agonist

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40083601

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant